» Articles » PMID: 173827

The Occurrence of Hepatoma in the Chronic Form of Hereditary Tyrosinemia

Overview
Journal J Pediatr
Specialty Pediatrics
Date 1976 Mar 1
PMID 173827
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

A 5 1/2-year-old child with hepatocarcinoma complicating hereditary tyrosinemia is presented. A review of the literature and an attempted follow-up of previously reported patients with the chronic form of hereditary tyrosinemia have disclosed 16 cases of hepatocarcinoma occurring in 43 patients surviving beyond 2 years of age (37%). This incidence is considerably higher than that generally given for the occurrence of hepatoma in adults with macronodular cirrhosis. Females and males are equally at risk. Additional factors beyond the development of cirrhosis are likely operative in the induction of hepatocarcinoma in patients with this metabolic disorder; those surviving beyond infancy are at considerable risk for the development of fatal hepatic neoplasms.

Citing Articles

Precision oncology through next generation sequencing in hepatocellular carcinoma.

Shinde S, Bigogno C, Simmons A, Kathuria N, Ghose A, Apte V Heliyon. 2025; 11(3):e42054.

PMID: 39927143 PMC: 11804570. DOI: 10.1016/j.heliyon.2025.e42054.


Liver tumors in children with chronic liver diseases.

Sintusek P, Phewplung T, Sanpavat A, Poovorawan Y World J Gastrointest Oncol. 2021; 13(11):1680-1695.

PMID: 34853643 PMC: 8603454. DOI: 10.4251/wjgo.v13.i11.1680.


Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Tang Y, Kong Y Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):514-523.

PMID: 34704422 PMC: 8777462. DOI: 10.3724/zdxbyxb-2021-0255.


Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.

Li S, Saviano A, Erstad D, Hoshida Y, Fuchs B, Baumert T J Clin Med. 2020; 9(12).

PMID: 33255794 PMC: 7760293. DOI: 10.3390/jcm9123817.


Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.

van Ginkel W, Rodenburg I, Harding C, Hollak C, Heiner-Fokkema M, van Spronsen F Paediatr Drugs. 2019; 21(6):413-426.

PMID: 31667718 PMC: 6885500. DOI: 10.1007/s40272-019-00364-4.